Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Protein Page:
PSMA2 (human)
rdtyret
p Phosphorylation
ac Acetylation
me Methylation
m1 Mono-methylation
m2 Di-methylation
m3 Tri-methylation
ub Ubiquitylation
sm Sumoylation
ne Neddylation
gl O-GlcNAc
ga O-GalNAc
pa Palmitoylation
ad Adenylation
sn S-Nitrosylation
ca Caspase cleavage
sc Succinylation

Overview
PSMA2 a proteasomal protein of the T1A peptidase family. The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. The component C3 may have a potential regulatory effect on another component(s) of the proteasome complex through tyrosine phosphorylation. Note: This description may include information from UniProtKB.
Protein type: Protease; Proteasome complex; EC 3.4.25.1
Chromosomal Location of Human Ortholog: 7p13
Cellular Component: cytosol; nucleoplasm; nucleus; proteasome complex; proteasome core complex
Molecular Function: protein binding; threonine endopeptidase activity
Biological Process: activation of MAPKK activity; anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process; antigen processing and presentation of exogenous peptide antigen via MHC class I; antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent; antigen processing and presentation of peptide antigen via MHC class I; apoptosis; axon guidance; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; epidermal growth factor receptor signaling pathway; fibroblast growth factor receptor signaling pathway; G1/S transition of mitotic cell cycle; gene expression; innate immune response; insulin receptor signaling pathway; MAPKKK cascade; mitotic cell cycle; negative regulation of apoptosis; negative regulation of ubiquitin-protein ligase activity during mitotic cell cycle; nerve growth factor receptor signaling pathway; polyamine metabolic process; positive regulation of ubiquitin-protein ligase activity during mitotic cell cycle; programmed cell death; protein polyubiquitination; Ras protein signal transduction; regulation of amino acid metabolic process; regulation of apoptosis; regulation of mRNA stability; regulation of ubiquitin-protein ligase activity during mitotic cell cycle; response to virus; small GTPase mediated signal transduction; stimulatory C-type lectin receptor signaling pathway; T cell receptor signaling pathway; tumor necrosis factor-mediated signaling pathway; vascular endothelial growth factor receptor signaling pathway; viral reproduction
Reference #:  P25787 (UniProtKB)
Alt. Names/Synonyms: HC3; Macropain subunit C3; MU; Multicatalytic endopeptidase complex subunit C3; PMSA2; proteasome (prosome, macropain) subunit, alpha type, 2; Proteasome component C3; Proteasome subunit alpha type-2; proteasome subunit HC3; PSA2; PSC2; PSC3; PSMA2
Gene Symbols: PSMA2
Molecular weight: 25,899 Da
Basal Isoelectric point: 6.91  Predict pI for various phosphorylation states
Protein-Specific Antibodies or siRNAs from Cell Signaling Technology® Total Proteins
Select Structure to View Below

PSMA2

Protein Structure Not Found.


STRING  |  cBioPortal  |  Wikipedia  |  Reactome  |  neXtProt  |  Protein Atlas  |  BioGPS  |  Scansite  |  Pfam  |  RCSB PDB  |  ENZYME  |  Phospho.ELM  |  NetworKIN  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene  |  InnateDB


Modification Sites and Domains  
Click here to view other types of protein modifications

Modification Sites in Parent Protein, Orthologs, and Isoforms  
 

Show Multiple Sequence Alignment


 LTP 

LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


 HTP 

HTP: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


       human

 
0 10 Y6‑p __MAERGysFsLTTF
0 16 S7‑p _MAERGysFsLTTFs
0 2 S9‑p AERGysFsLTTFsPs
0 3 S14‑p sFsLTTFsPsGKLVQ
0 2 S16‑p sLTTFsPsGKLVQIE
0 145 Y24‑p GKLVQIEyALAAVAG
0 1 S35‑p AVAGGAPsVGIkAAN
0 7 K39‑ub GAPsVGIkAANGVVL
0 23 K50‑ub GVVLATEkkQkSILy
0 1 K50‑ac GVVLATEkkQkSILy
0 6 K51‑ub VVLATEkkQkSILyD
0 2 K53‑ac LATEkkQkSILyDER
0 10 K53‑ub LATEkkQkSILyDER
0 135 Y57‑p kkQkSILyDERSVHk
0 1 K64 yDERSVHKVEPITkH
0 33 K64‑ub yDERSVHkVEPITkH
0 1 K64‑sc yDERSVHkVEPITkH
0 104 K70‑ub HkVEPITkHIGLVys
0 1 K70‑ac HkVEPITkHIGLVys
0 842 Y76‑p TkHIGLVysGMGPDY
0 18 S77‑p kHIGLVysGMGPDYR
0 70 K92‑ub VLVHRARkLAQQyyL
0 3 K92‑ac VLVHRARkLAQQyyL
0 15 Y97‑p ARkLAQQyyLVyQEP
0 44 Y98‑p RkLAQQyyLVyQEPI
0 380 Y101‑p AQQyyLVyQEPIPTA
1 0 Y121 VASVMQEYTQSGGVR
0 28 K165‑ub WKATAMGkNyVNGkT
0 5 Y167‑p ATAMGkNyVNGkTFL
0 12 K171‑ac GkNyVNGkTFLEkRY
0 27 K171‑ub GkNyVNGkTFLEkRY
0 1 K171 GkNyVNGKTFLEkRY
0 12 K176‑ub NGkTFLEkRYNEDLE
0 19 K227‑ub RLTPTEVkDYLAAIA
  mouse

 
Y6‑p __MAERGysFSLTTF
S7‑p _MAERGysFSLTTFS
S9 AERGysFSLTTFSPS
S14 sFSLTTFSPSGKLVQ
S16 SLTTFSPSGKLVQIE
Y24‑p GKLVQIEyALAAVAG
S35 AVAGGAPSVGIKAAN
K39 GAPSVGIKAANGVVL
K50‑ub GVVLATEkKQkSILy
K50 GVVLATEKKQkSILy
K51 VVLATEkKQkSILyD
K53 LATEkKQKSILyDER
K53‑ub LATEkKQkSILyDER
Y57‑p kKQkSILyDERSVHK
K64 yDERSVHKVEPITkH
K64 yDERSVHKVEPITkH
K64 yDERSVHKVEPITkH
K70‑ub HKVEPITkHIGLVys
K70 HKVEPITKHIGLVys
Y76‑p TkHIGLVysGMGPDY
S77‑p kHIGLVysGMGPDYR
K92‑ub VLVHRARkLAQQyyL
K92 VLVHRARKLAQQyyL
Y97‑p ARkLAQQyyLVyQEP
Y98‑p RkLAQQyyLVyQEPI
Y101‑p AQQyyLVyQEPIPTA
Y121 VASVMQEYTQSGGVR
K165‑ub WKATAMGkNyVNGkT
Y167‑p ATAMGkNyVNGkTFL
K171‑ac GkNyVNGkTFLEKRY
K171‑ub GkNyVNGkTFLEKRY
K171‑sc GkNyVNGkTFLEKRY
K176 NGkTFLEKRYNEDLE
R227 RLTPTEVRDYLAAIA
  rat

 
Y6 __MAERGYSFSLTTF
S7 _MAERGYSFSLTTFS
S9 AERGYSFSLTTFSPS
S14 SFSLTTFSPSGKLVQ
S16 SLTTFSPSGKLVQIE
Y24‑p GKLVQIEyALAAVAG
S35 AVAGGAPSVGIKAAN
K39 GAPSVGIKAANGVVL
K50 GVVLATEKKQkSILY
K50 GVVLATEKKQkSILY
K51 VVLATEKKQkSILYD
K53‑ac LATEKKQkSILYDER
K53 LATEKKQKSILYDER
Y57 KKQkSILYDERSVHk
K64‑ac YDERSVHkVEPITkH
K64 YDERSVHKVEPITkH
K64 YDERSVHKVEPITkH
K70‑ub HkVEPITkHIGLVyS
K70 HkVEPITKHIGLVyS
Y76‑p TkHIGLVySGMGPDY
S77 kHIGLVySGMGPDYR
K92 VLVHRARKLAQQYyL
K92‑ac VLVHRARkLAQQYyL
Y97 ARkLAQQYyLVyQEP
Y98‑p RkLAQQYyLVyQEPI
Y101‑p AQQYyLVyQEPIPTA
Y121‑p VASVMQEyTQSGGVR
K165 WKATAMGKNyVNGkT
Y167‑p ATAMGKNyVNGkTFL
K171‑ac GKNyVNGkTFLEKRY
K171 GKNyVNGKTFLEKRY
K171 GKNyVNGKTFLEKRY
K176 NGkTFLEKRYNEDLE
R227 RLTPTEVRDYLAAIA
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.